Ovarian Cancer
Conditions
Brief summary
The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.
Interventions
DEVICEDrug Response Predictor® (DRP)
A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.
Sponsors
Allarity Therapeutics
Amarex Clinical Research
Study design
Observational model
OTHER
Time perspective
OTHER
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histological confirmed epithelia ovarian cancer * Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible. * Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting * FFPE tumor tissue available
Exclusion criteria
* Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy. * Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of ovarian cancer patients with high likelihood of being sensitive to investigational cancer drug | up to 2 years | based on FFPE ovarian cancer tissue |
Secondary
| Measure | Time frame |
|---|---|
| Retrospective analysis of whether or not the DRP method can predict and confirm the obtained sensitivity to the prior drugs used in the treatment of ovarian cancer | up to 2 years |
Countries
United Kingdom, United States
Contacts
CONTACTUS: Kathleen Moore
CONTACTEurope: Rebecca Kristeleit
Outcome results
None listed